InfraReDx Inc. of Burlington, Mass., has received 501(k) clearance from the FDA to market its near-infrared spectroscopic system for coronary artery examination. The corporation hopes that the catheter-based, fiber optic device, which has a laser light source, will enable cardiologists to characterize plaque composition and identify potentially rupture-prone lipid-based plaques. Recently, the company closed a $22.3 million round of funding to complete studies and finalize product development in preparation for a 2007 launch of the device.